AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 31 min read$BWAYNeutralLow

Roth Yiftach sold 1,000 shares of BWAY

Roth Yiftach (Chief Scientist) sold 1,000 shares of Brainsway Ltd. (BWAY) on 2026-06-02.

Roth YiftachJune 3, 2026
AI analysis
Relevance
4/10
Novelty
3/10
Actionability
Low
Sentiment · $BWAY
Neutral
Timing
Filed today; sale occurred on 2026-06-02
Market alignment
Neutral—insider sale without disclosed value typically doesn’t drive a directional repricing alone
Why this matters for $BWAY

Insider selling is disclosed, but the filing provides no price/value or signaling context beyond a routine sale.

Relevance context

SEC Form 4 shows Chief Scientist Roth Yiftach sold 1,000 shares of Brainsway (BWAY) in an open-market transaction.

Price-impact prediction

Likely limited near-term impact; treat as low-signal unless paired with other disclosures.

Background

The article is an SEC Form 4 insider transaction disclosure (officer/direct holdings change).

Why it matters

This provides a new, transaction-level datapoint but lacks fundamental drivers (no earnings, guidance, deal, or regulatory event).

Market relevance

Traders may note insider selling as a sentiment input, but the filing alone is unlikely to be a standalone catalyst.

Market effects

Sector

Minimal—single-company insider transaction with no operational or regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Alternative perspectives

Contrarian view

If insiders are consistently net sellers, the stock could face gradual sentiment pressure even without a single large trade.

Overlooked factors

The sale’s motivation is unclear (taxes, diversification, liquidity). Without disclosed price/value and with no 10b5-1 plan, interpretation is especially uncertain.

Key entities

  • insider
    Roth Yiftach

    Chief Scientist at Brainsway; reported an open-market sale of 1,000 shares.

  • issuer
    Brainsway Ltd.

    Issuer of the securities subject to the Form 4; ticker BWAY.

Read at source← All news

Related articles

MAY 27
$HELPLow

PRISM MarketView Spotlights Seven Public Companies Advancing Mental Health Innovation During National Mental Health Awareness Month

PRISM MarketView highlighted seven public companies developing mental health therapies, devices, and digital platforms during National Mental Health Awareness Month. Featured firms include Helus Pharma (HELP), GH Research (GHRS), AtaiBeckley (ATAI), Definium Therapeutics (DFTX), BrainsWay (BWAY), Neuronetics (STIM), and Talkspace (TALK), spanning psychedelic-derived treatments, TMS, and virtual care.

manilatimes.net4 min
MAY 13
$BWAYMed

BrainsWay stock falls over 2% despite beating Q1 estimates on guidance

BrainsWay Ltd. (NASDAQ:BWAY) reported strong Q1 2026 results, surpassing analyst estimates with adjusted EPS of $0.06 and revenue growth of 35% year-over-year to $15.5 million. Despite beating expectations and shipping a record number of Deep TMS systems, the company's stock fell over 2% in pre-market trading as investors reacted to its reiterated full-year guidance, which remained largely in line with analyst consensus. BrainsWay also highlighted significant progress in expanding Deep TMS awareness, broader reimbursement, and secured the first insurer coverage for its accelerated SWIFT Deep TMS protocol.

Investing.com Nigeria4 min
FEB 19
$BWAYMed

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

BrainsWay, a leader in neurostimulation treatments, has invested $1.0 million, with a potential for an additional $1.5 million, in BrainStim Health Inc., a Canadian mental health provider. This minority-stake investment aims to expand access and awareness of Deep TMS technology in North America. BrainsWay views this as part of a broader strategy to support growth-oriented clinical service platforms while focusing on scientific and clinical advancement.

GlobeNewswire3 min